May 1 (Reuters) - Eli Lilly and Co LLY.N:
ELI LILLY EXEC SAYS ANNOUNCED TARIFFS CURRENTLY IN EFFECT DO NOT MATERIALLY CHANGE CO'S 2025 FINANCIAL OUTLOOK - CONF CALL
LILLY EXEC SAYS EXPANSION OF TARIFFS IN OTHER GEOGRAPHIES OR INCREASES IN RETALIATORY TARIFFS WOULD HAVE A NEGATIVE EFFECT ON CO, INDUSTRY
LILLY EXEC SAYS RECENTLY INITIATED LIMITED MOUNJARO LAUNCH IN CHINA, EXPECT TO TO GRADUALLY INCREASE LAUNCH IN H2 AS SUPPLY BECOMES AVAILABLE
LILLY EXEC SAYS EXPECT US REGULATORY ACTION FOR MODIFIED DOSING REGIME FOR ALZHEIMER'S DRUG KISUNLA IN THE NEXT FEW MONTHS
LILLY EXEC SAYS PLANS TO START A NEW LATE-STAGE TRIAL FOR ITS DRUG RETATRUTIDE IN PATIENTS WITH OBESITY AND CHRONIC LOW BACK PAIN
LILLY EXEC SAYS CO HAS WITHDRAWN US APPLICATION FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION INDICATION FOR TIRZEPATIDE
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.